Physician profile
Daniel L Lowder
NPI 1992102834
$1,030.76
in general payments reported to CMS, 2019-2025
15 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $335 · 2024: $476 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $156.88 | 2024 | Spravato |
| Corium, LLC | $156.19 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.06 | 2023-2025 | Caplyta |
| Lundbeck LLC | $130.63 | 2023-2025 | Rexulti |
| Brainsway USA INC | $63.79 | 2025 | Deep Tms System |
| Abbvie INC. | $61.24 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.96 | 2023-2024 | Trintellix |
| Axsome Therapeutics, INC. | $53.48 | 2023-2025 | Auvelity |
| Alkermes, INC. | $52.68 | 2023 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $40.00 | 2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $39.67 | 2025 | Qelbree |
| Tempus Ai, INC | $30.11 | 2024 | |
| Biogen, INC. | $20.50 | 2024 | |
| Tris Pharma INC | $18.22 | 2023 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $15.35 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lowder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.